首页> 外文期刊>The Annals of Thoracic Surgery: Official Journal of the Society of Thoracic Surgeons and the Southern Thoracic Surgical Association >The Effect of Pregabalin and Methylcobalamin Combination on the Chronic Postthoracotomy Pain Syndrome
【24h】

The Effect of Pregabalin and Methylcobalamin Combination on the Chronic Postthoracotomy Pain Syndrome

机译:普瑞巴林和甲钴胺联合治疗对慢性开胸术后疼痛综合征的影响

获取原文
           

摘要

Background Chronic postthoracotomy pain (CPTP) consists of different types of pain. Some characteristics of CPTP are the same as those of recognized neuropathic pain syndromes. We aimed to determine the safety and efficacy of pregabalin and methylcobalamin combination (PG-B12) in comparison with diclofenac potassium (DP) in patients with CPTP.;Methods One hundred consecutive patients with CPTP after posterolateral/lateral thoracotomy were prospectively randomly assigned and evaluated. Fifty patients were given PG-B12 and another 50 patients were given DP treatment. Visual Analogue Scale (VAS) and the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) scorings were performed previous to the treatment (day 0) and on the 15th, 30th, 60th, and 90th days. Adverse events were questioned.;Results The mean ages were 58.7 ± 12.2 and 54.6 ± 14.5 years, and the mean durations of pain were 4.01 ± 1.04 and 3.8 ± 1.02 months, respectively. The number of patients with a VAS score less than 5 at the latest follow-up (VAS90 < 5) was 44 (88%) and 18 (36%) in the PG-B12 and DP groups, respectively (p < 0.05). Forty-four patients (88%) in the PG-B12 group and 16 patients (32%) in the DP group had a LANSS score less than 12 at the latest follow-up (p < 0.05). Minor adverse events that did not mandate discontinuation of the treatment were observed in 14 patients (28%) in the PG-B12 group and 2 patients (4%) in the DP group.;Conclusions PB-B12 is safe and effective in the treatment of CPTP with minimal side effects and a high patient compliance. These results should be supported by multidisciplinary studies with larger sample sizes and longer follow-ups.;Chronic postthoracotomy pain (CPTP) or postthoracotomy neuralgia is defined by the International Association for the Study of Pain as pain that recurs or persists along a thoracotomy incision for at least 2 months after the surgical procedure [1][1]. Usually, it is a burning, dysesthetic, and aching feeling in nature, which displays many features of neuropathic pain. It occurs in approximately 50% of patients after thoracotomy; however, in 5% of patients the pain is severe and disabling. The technique of different thoracotomy incisions has been shown to have no difference in reducing the incidence of CPTP [2, 3]. The neurologic mechanisms for the production of neuropathic pain, hyperalgesia, and somatic pain are well described [4, 5, 6, 7]. These conditions are controlled by a variety of drugs that include nonsteroidal anti-inflammatory drugs, parenteral opiates, epidurals,?and paravertebral infusions of local anesthetics, narcotics,?intrapleural analgesia, transcutaneous nerve stimulation, intercostal and phrenic nerve blockades, and cryotherapy [6, 7, 8, 9, 10, 11, 12]. However, the results were variable, and no single strategy was shown to be effective in all patients.We administered pregabalin and vitamin B12 combination (PG-B12), an anticonvulsant and methylcobalamin, to the patients with CPTP and compared its effectiveness with diclofenac potassium (DP), a nonsteroidal anti-inflammatory drug, used in conventional pain treatment. There is only one prospective study and a case report about PG-B12 combination treatment in CPTP.Jump to SectionPatients and MethodsStudy PopulationDrug Admission ProtocolStatistical AnalysisResultsCommentReferences;Jump to SectionPatients and MethodsStudy PopulationDrug Admission ProtocolStatistical AnalysisResultsCommentReferences;One hundred consecutive patients with CPTP were included in the study. After getting approval from the institutional review board, this study was conducted in the Department of Thoracic Surgery, Sureyyapasa Pulmonology and Thoracic Surgery Training and Research Hospital, on 100 consenting patients who underwent thoracotomies. Postoperative pain that did not respond to a conventional treatment of at least 3 months’ duration was accepted as chronic pain. The severity of wound pain was determined using a 10-point Visual Analogue Scale
机译:背景慢性开胸术后疼痛(CPTP)由不同类型的疼痛组成。 CPTP的某些特征与公认的神经性疼痛综合征的特征相同。我们旨在确定普瑞巴林和甲基钴胺素联合用药(PG-B12)与双氯芬酸钾(DP)在CPTP患者中的安全性和有效性。方法前瞻性随机分配并评估了后外侧/外侧开胸手术后连续100例CPTP患者。 50名患者接受了PG-B12治疗,另外50名患者接受了DP治疗。在治疗前(第0天)和第15、30、60和90天进行视觉模拟量表(VAS)和利兹病神经症状和体征的利兹评估(LANSS)评分。结果:平均年龄为58.7±12.2个月和54.6±14.5岁,平均疼痛持续时间分别为4.01±1.04和3.8±1.02个月。在PG-B12和DP组中,最近一次随访(VAS90 <5)时VAS评分低于5的患者人数分别为44(88%)和18(36%)(p <0.05)。在最近的随访中,PG-B12组的44例患者(88%)和DP组的16例患者(32%)的LANSS评分低于12(p <0.05)。 PG-B12组的14例患者(28%)和DP组的2例患者(4%)观察到了不要求停止治疗的轻微不良事件。结论PB-B12是安全有效的治疗方法CPTP具有最小的副作用和较高的患者依从性。这些结果应得到更大样本量和更长随访时间的多学科研究的支持;国际疼痛研究协会将慢性开胸术后疼痛(CPTP)或开胸术后神经痛定义为在开胸切口处复发或持续存在的疼痛手术后至少2个月[1] [1]。通常,它是自然界中的一种灼热,知觉和疼痛的感觉,表现出神经性疼痛的许多特征。开胸手术后约有50%的患者会发生这种情况;但是,在5%的患者中,疼痛严重且致残。业已证明,不同的开胸切口技术在降低CPTP发生率方面没有差异[2,3]。产生神经性疼痛,痛觉过敏和躯体疼痛的神经机制已得到很好的描述[4、5、6、7]。这些情况由多种药物控制,包括非甾体类抗炎药,肠胃外阿片类药物,硬膜外麻醉药和局部麻醉药,麻醉药,胸膜内镇痛药,经皮神经刺激,肋间和神经阻滞以及冷冻疗法[6] ,7,8,9,10,11,12]。然而,结果是可变的,并且没有一种方法对所有患者有效。我们对CPTP患者使用了普瑞巴林和维生素B12组合(PG-B12),抗惊厥药和甲基钴胺素,并将其与双氯芬酸钾进行了比较(DP),一种非甾体类抗炎药,用于常规疼痛治疗。仅有一项关于PG-B12联合治疗CPTP的前瞻性研究和一例病例报告。跳转至部分患者和方法研究人群药物许可协议统计分析结果评论参考;跳转至部分患者和方法研究人群药物许可协议统计分析结果评论评论;连续纳入100例CPTP患者。在获得机构审查委员会的批准后,这项研究是在Sureyyapasa肺科和胸外科培训研究医院的胸外科进行的,对100例接受了胸腔切除术的患者进行了同意。对于常规疼痛至少持续3个月没有反应的术后疼痛,被视为慢性疼痛。使用10分视觉模拟量表确定伤口疼痛的严重程度

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号